Sustained fat loss requires suppressing appetite, enhancing lipolysis, improving insulin sensitivity, and preserving lean mass during caloric restriction. Modern peptide research — particularly triple agonist and mitochondrial approaches — has produced fat loss results previously only possible with bariatric surgery, while simultaneously improving metabolic health markers.
1. Retatrutide — Triple GLP-1/GIP/Glucagon Agonist
Retatrutide combines GLP-1, GIP, and glucagon receptor activation — producing the highest fat loss of any peptide studied to date. Phase 2 trials demonstrated up to 24% body weight reduction over 48 weeks. The added glucagon component directly increases energy expenditure and hepatic fat oxidation beyond what dual agonists achieve, pushing fat loss into territory previously impossible without surgery.
Dosing Protocol: 2 mg SubQ once weekly (starting dose). Titrate by 2 mg every 4 weeks to target dose of 8–12 mg/week based on tolerance and response. Still in clinical development — follow emerging protocols closely.
2. 5-Amino-1MQ — NNMT Inhibition / Visceral Fat Targeting
5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase) in adipocytes, restoring NAD+ levels and activating AMPK-driven fat oxidation within fat cells. It forces visceral adipocytes from an energy-storing to an energy-expending phenotype, reducing visceral fat mass at the cellular level — a mechanism completely independent of and complementary to appetite suppression.
Dosing Protocol: 50–100 mg oral daily. Cycle: 4–8 weeks.
3. MOTS-C — Mitochondrial Fat Burning / AMPK
MOTS-C is a mitochondria-derived peptide that activates AMPK in skeletal muscle and adipose tissue, enhancing cellular glucose uptake and fat oxidation independent of insulin or appetite. In fat loss protocols, MOTS-C improves metabolic flexibility — increasing the proportion of fat oxidized at rest and during exercise — and mimics key metabolic effects of caloric restriction at the cellular level.
Dosing Protocol: 5–10 mg SubQ 3–5x per week. Best timed around physical activity. Cycle: 4–8 weeks.
Retatrutide provides the most powerful appetite suppression and energy expenditure increase available through GLP-1/GIP/glucagon triple agonism — driving the caloric deficit needed for significant fat loss. 5-Amino-1MQ targets visceral adipocytes directly, forcing fat cells into oxidation mode independent of caloric intake. MOTS-C activates mitochondrial AMPK pathways that improve whole-body metabolic flexibility and fat oxidation efficiency — creating a triple-mechanism approach that addresses fat loss from the top down (appetite), the cell level (NNMT inhibition), and the mitochondrial level (AMPK activation).
- Jastreboff AM et al. (2023). Retatrutide Phase 2 obesity trial — 24% weight loss. NEJM. DOI: 10.1056/NEJMoa2301972
- Lee C et al. (2023). MOTS-C and mitochondrial metabolic regulation. Nature Medicine. DOI: 10.1038/s41591-023-02399-0
- Kannt A et al. (2019). 5-Amino-1MQ NNMT inhibition and adipose fat loss. Cell Metabolism. DOI: 10.1016/j.cmet.2019.05.009
- Jastreboff AM et al. (2022). Tirzepatide dual agonism comparison. NEJM. DOI: 10.1056/NEJMoa2206038
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).